Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 01/07/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1087 publications
Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 12, 2025
Comparative cost-effectiveness of ribociclib and palbociclib as first-line treatment for HR+/HER2- advanced breast cancer in postmenopausal women: analysis from a Medicare perspective.
Journal: Journal of medical economics
Published: December 08, 2025
Cost-effectiveness analysis of ribociclib versus abemaciclib as first-line treatments for postmenopausal women with HR+/HER2- advanced breast cancer: a Medicare perspective.
Journal: Journal of medical economics
Published: December 05, 2025
Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Global Challenges and Tibremciclib Perspective.
Journal: JCO global oncology
Published: December 04, 2025
Impact of CDK4/6 inhibitors on health-related quality of life outcomes in patients with metastatic breast cancer: A systematic review and meta-analysis.
Journal: Journal of managed care & specialty pharmacy
Published: November 26, 2025
Cost-effectiveness analysis of ribociclib versus palbociclib as a first line therapy in HR+/HER2- advanced breast cancer: evidence from the Chilean Public Health system.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: November 21, 2025
Retraction Note: Combined Ribociclib and NU7026 administration enhances radio-sensitivity by inhibiting DNA repair in prostate cancer.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: November 10, 2025
Considerations for emulations of randomized controlled trials using real-world data: learnings from an emulation of MONALEESA-2.
Journal: Journal of comparative effectiveness research
Published: October 28, 2025
Identifying informative censoring from censoring patterns across successive follow-ups.
Journal: European journal of cancer (Oxford, England : 1990)
Published: October 26, 2025
Real-world outcomes with palbociclib, ribociclib, and abemaciclib plus endocrine therapy in HR+/HER2- advanced breast cancer: A multicenter retrospective study.
Journal: Breast (Edinburgh, Scotland)
Published: October 12, 2025
Reconciling Sentinel Node Omission with CDK4/6 Inhibitor Eligibility in HR+/HER2- Early Breast Cancer: A Real-World Cohort Analysis.
Journal: Clinical breast cancer
Published: October 08, 2025
Last Updated: 01/07/2026